pharma news today obesity drugs glp-1 today health october 2025 Outlook for obesity in 2025: more U.S. FDA | FDA today

Its worth noting that some providers do offer lower per-month pricing when you commit to a longer plan

From Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity: In the remote study, we observe a significantly lower self-reported intake of alcohol, drinks per drinking episode, binge drinking odds, Alcohol Use Disorders Identification Test (AUDIT) scores, and stimulating, and sedative effects in the Semaglutide or Tirzepatide group when compared to prior to starting medication timepoint (within-subjects) and the control group (between-subjects)

Frias, J

Here are the key results from landmark trials that established its clinical credibility

Hypertension (2009) 54(1):406

("PolyPid" or the "Company"), unveiled its long-acting GLP-1 receptor agonists (glucagon-like peptide-1 RA) delivery platform which aims to subcutaneously release GLP-1 RA for approximately 60 days, significantly longer than current weekly injection regimens